Munich’s Tubulis Raises €308M To Accelerate Antibody-Drug Conjugate Development

Based in Munich, Tubulis develops precision ADCs that pair antibodies with potent drugs to target cancer cells. The funding will accelerate clinical development of lead candidate TUB-040, targeting NaPi2b in ovarian and lung cancers, currently in Phase I/IIa and granted FDA Fast Track in 2024.

The round was led by Venrock Healthcare Capital Partners, with Wellington Management, Ascenta Capital, and existing investors including Nextech Invest, EQT Life Sciences, and Seventure Partners.

Read Also - Omnia Raises €3.5M To Boost Brands On AI Platforms

Funds will also advance Tubulis’ pipeline, including TUB-030, preclinical programs, and proprietary ADC platform technologies, aiming to improve therapeutic outcomes for solid tumours.

“This landmark financing round reflects the deep conviction these global healthcare investors have in Tubulis and the disruptive potential of our ADC platforms,” said Dr. Dominik Schumacher CEO and Co-founder of Tubulis. “With TUB-040 progressing in the clinic and first data to be shared in a late-breaking oral presentation at ESMO, we are ready to expand into earlier treatment lines, while continuing to innovate across our pipeline and technology platforms. The new funding empowers us to execute on our vision of creating truly differentiated antibody-drug conjugates that are tailored to the biology of solid tumours and can deliver superior therapeutic value to patients.”

HTGF (High-Tech Gründerfonds), an early Tubulis supporter, renewed and increased its investment in this round. Having co-led the 2020 Series A, HTGF has backed the company from inception to clinical development, highlighting Germany’s biotech innovation strength and its capacity to attract private capital for advanced technologies.

“HTGF was one of our earliest investors and supported us in shaping Tubulis during its formative years. Their renewed commitment in this round reflects the continued partnership and shared belief in our mission to expand the therapeutic potential of ADCs for patients worldwide,” said Dr. Dominik Schumacher, CEO and Co-founder of Tubulis.

Dr. Frank Hensel, Principal at HTGF, added: “Our relationship with Tubulis has always been built on trust and a shared ambition to redefine oncology treatment. This latest round supported by leading global investors, validates the strength of the platform and the team. We are proud to continue backing Tubulis as it enters a pivotal phase of clinical development.”

Dr. Achim Plum, Managing Director at HTGF, said: “Tubulis’ Series C demonstrates that even highly capital-intensive, disruptive technologies can attract the private funding needed to bring cutting-edge therapies to patients. For us at HTGF, Tubulis is a prime example of how we operate: we engage very early, often before a company is founded, and build trusted relationships with exceptional teams. This story reflects our belief in scientific excellence, entrepreneurial vision, and the impact that can be achieved when both come together. Congratulations to the entire Tubulis team on this outstanding success.”

Tubulis’ innovative ADC technologies have established it as a leading European biotech company. Leveraging cutting-edge science, clinical progress, and strong investor support, the firm is advancing its mission to broaden ADC-based cancer therapies globally.

About Tubulis

Tubulis® develops precision antibody-drug conjugates (ADCs) by combining proprietary technologies with disease-specific biology. Focused on expanding ADC therapeutic potential, the company advances its own pipeline and supports partners, aiming to deliver improved patient outcomes across diverse indications.